Journal of South Asian Federation of Obstetrics and Gynaecology

Register      Login

VOLUME 13 , ISSUE 3 ( May-June, 2021 ) > List of Articles

Original Article

Magnesium Sulfate for Fetal Neuroprotection in Women at Risk of Preterm Birth: Analysis of its Effect on Cerebral Palsy

Nidhi Gupta, Ruchika Garg, Akanksha Gupta, Shivani Mishra

Keywords : Cerebral palsy, Fetal neuroprotection, Magnesium sulfate, Preterm labor

Citation Information : Gupta N, Garg R, Gupta A, Mishra S. Magnesium Sulfate for Fetal Neuroprotection in Women at Risk of Preterm Birth: Analysis of its Effect on Cerebral Palsy. J South Asian Feder Obs Gynae 2021; 13 (3):90-93.

DOI: 10.5005/jp-journals-10006-1907

License: CC BY-NC 4.0

Published Online: 09-09-2021

Copyright Statement:  Copyright © 2021; The Author(s).


Background: Magnesium sulfate (MgSO4) can be used for the primary prevention of cerebral palsy in preterm infants less than 37 weeks of gestational age. Aim and objective: To assess the effect of MgSO4 given for fetal neuroprotection to women at risk of preterm birth. Materials and Methods: This study was conducted on 100 women admitted to labor room in the Department of Obstetrics and Gynecology, S.N. Medical College, Agra, between August 2018 and December 2020. These women were randomly distributed into two groups. Women taken for study underwent detailed history, examination, and baseline investigations. In group 1, 50 women at risk of preterm birth before 37 weeks (gestational age, 28–36 weeks 6D) of gestation were given MgSO4, 4 g bolus over 20–30 minutes followed by 1 g/hour, whereas in group 2, 50 women were not given MgSO4. Results: In our study, the majority of the patients were between the gestational age of 31 and 34 weeks. The mean gestational age was 30.1 weeks in group 1 and 31.5 weeks in group 2. The difference in terms of birth weight between the two groups is statistically insignificant. Neonatal outcomes among women administered MgSO4 and women not administered MgSO4 include the following: Neonatal seizures (2 vs 4%), respiratory distress (46 vs 60%), mechanical ventilation (48 vs 62%), and neonatal enterocolitis (6 vs 0.5%). The difference between Apgar scores of the two groups is statistically insignificant. Resuscitation was needed, 4 versus 6%, in group 2. There were 1 mortality in group 1 and 2 in group 2. In group 1, 44% of neonates needed neonatal intensive care unit (NICU) admission, whereas in group 2, 62.5% of neonates needed NICU admission with a p value of 0.03095, which is found to be not significant between the two groups. In neonates of group 1, the cases administered MgSO4 did not show the sign of intraventricular hemorrhage or periventricular leukomalacia, while on the contrary, in neonates of group 2, 4% had ultrasonography suggestive of intraventricular hemorrhage and 6% had periventricular leukomalacia with a p value of 0.14, which is statistically insignificant. Maternal side effects, such as flushing (66 vs 6%), nausea (16 vs 2%), sweating (28 vs 4%), hypotension (2%), tachycardia (4% in group 1), and postpartum hemorrhage, were seen in 4% of women administered MgSO4 and 2% of cases in group 2. No serious side effects were attributed to MgSO4, and the commonest side effect was flushing. Administering MgSO4 with a large margin of safety in preterm births may help to prevent the development of cerebral palsy in preterm infants. As MgSO4 is a safe, readily available inexpensive drug even if there are modest benefits for its use, the risk-benefit is in favor of its use. Conclusion: MgSO4 is the drug currently administered to mothers at the risk of preterm labor for fetal neuroprotection. Further multicenter studies with larger sample sizes exploring immediate adverse outcomes in magnesium-exposed neonates correlated with their serum magnesium concentrations are needed. Further prospective studies must be performed to determine the optimal dose of maternal magnesium for different subgroups of mothers to provide fetal neuroprotection with minimal neonatal adverse outcomes. In the meantime, there is a need for guidelines on the use of MgSO4.

  1. Agustin CA, Roberto R. Antenatal magnesium sulfate for the prevention of cerebral palsy in preterm infants <34 weeks’ gestation: a systematic review and metaanalysis. Am J Obstet Gynecol 2009;200(6):595–609. DOI: 10.1016/j.ajog.2009.04.005.
  2. Clark GD, Rothman SM. Blockade of excitatory amino acid receptors protects anoxic hippocampal slices. Neuroscience 1987;21(3):665– 671. DOI: 10.1016/0306-4522(87)90027-3.
  3. McIntosh TK, Vink R, Yamakami I, et al. Magnesium protects against neurological deficit after brain injury. Brain Res 1989;482(2):252–260. DOI: 10.1016/0006-8993(89)91188-8.
  4. Leviton A, Kuban KCK, Pagano M, et al. Maternal toxemia and neonatal germinal matrix hemorrhage in intubated infants less than 1751 g – In reply. Obstet Gynecol 1989;73:683.
  5. Nelson KB, Grether JK. Can magnesium sulfate reduce the risk of cerebral palsy in very low birthweight infants? Pediatrics 1995;95:263–269.
  6. Rouse DJ, Hirtz DG, Thom EA, Eunice Shriver Kennedy National Institute of Child Health and Human Development Maternal - Fetal Medicine Units Network. Magnesium sulfate for the prevention of Cerebral Palsy. Rply N Engl J Med 2009;360:190.
  7. Crowther CA, Hiller JE, Doyle LW, Haslam RR. Australasian Collaborative Trial of Magnesium Sulphate (ACTO MgSO4) Collaborative Group. Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. JAMA 2003;290:2669– 2676. DOI: 10.1001/jama.290.20.2669.
  8. Marret S, Marpeau L, Follet-Bouhamed C, Cambonie G, Astruc D, Delaporte B. et al. [Effect of magnesium sulphate on mortality and neurologic morbidity of the very-preterm newborn (of less than 33 weeks) with two year neurological outcome: results of the Bibliography [69] prospective PREMAG trial]. Gynecol Obstet Fertil 2008;36:278–288. DOI: 10.1016/j.gyobfe.2008.01.012.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.